Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Epilepsy ll: Types01:22

Epilepsy ll: Types

Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comment on: Lee J.Z.C. et al. Case report: Hepatocellular carcinoma in a patient with Pyridoxamine 5-phosphate oxidase (PNPO) deficiency undergoing pyridoxal 5-phosphate (PLP) treatment. Mol Genet Metab Rep. 2025;9;43:101224.

Molecular genetics and metabolism reports·2026
Same author

Evolution of neuroimaging features in children with acute flaccid myelitis compared to other forms of childhood myelitis.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society·2025
Same author

Clinical presentation, MR imaging and outcome in children with myelin oligodendrocyte glycoprotein antibody-negative acute disseminated encephalomyelitis.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society·2025
Same author

Corrigendum to "Autoantibody status, neuroradiological and clinical findings in children with acute cerebellitis" [Eur. J. Paediatr. Neurol. 47 (2023) 118-130].

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society·2024
Same author

Frequency of an intrathecal IgM synthesis and MRZ reaction in children with MS.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society·2024
Same author

Autoantibody status, neuroradiological and clinical findings in children with acute cerebellitis.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society·2024

Related Experiment Video

Updated: Jun 17, 2026

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Epilepsy in patients with propionic acidemia.

E Haberlandt1, C Canestrini, M Brunner-Krainz

  • 1Clinical Department of Pediatrics, Division of Neonatology, Neuropediatrics and Inherited Metabolic Diseases, Medical University of Innsbruck, Innsbruck, Austria. edda.haberlandt@uki.at

Neuropediatrics
|December 19, 2009
PubMed
Summary
This summary is machine-generated.

Propionic acidemia (PA), a metabolic disorder, frequently causes abnormal EEG findings and epilepsy. Most affected patients developed seizures, with some experiencing fever-induced or absence epilepsy, highlighting the need for neurological monitoring.

More Related Videos

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats
08:47

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats

Published on: November 8, 2018

Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy
09:57

Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy

Published on: September 20, 2024

Related Experiment Videos

Last Updated: Jun 17, 2026

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats
08:47

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats

Published on: November 8, 2018

Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy
09:57

Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy

Published on: September 20, 2024

Area of Science:

  • Neurology
  • Metabolic Disorders
  • Clinical Neurophysiology

Background:

  • Propionic acidemia (PA) is an inherited metabolic disorder affecting propionyl-CoA carboxylase.
  • Limited data exists on electroencephalogram (EEG) findings and epilepsy development in PA patients.
  • Understanding neurological complications is crucial for managing PA.

Purpose of the Study:

  • To investigate EEG abnormalities and epilepsy incidence in patients with Propionic acidemia.
  • To identify specific seizure types and EEG patterns associated with PA.
  • To explore potential links between metabolic dysfunction and neurological outcomes.

Main Methods:

  • Retrospective analysis of EEG data and clinical histories from 17 PA patients across multiple centers.
  • Evaluation of background EEG activity, epileptiform discharges, and seizure types.
  • Assessment of treatment response to antiepileptic drugs (AEDs) and occurrence of photosensitivity.

Main Results:

  • Nine out of 17 PA patients exhibited abnormal EEG background activity and epileptiform discharges.
  • All nine patients with abnormal EEGs developed symptomatic epilepsy, including fever-induced seizures and absence epilepsy.
  • Four patients displayed photosensitivity, a previously unreported finding in PA. AEDs were generally well-tolerated.

Conclusions:

  • Patients with Propionic acidemia are susceptible to cortical dysfunction due to pathological metabolites.
  • Abnormal EEG findings and epilepsy are common in PA, necessitating vigilant neurological monitoring.
  • The high rate of seizures and novel findings like photosensitivity warrant further investigation into PA's neurobiological mechanisms.